Sirolimus reduced skin cancer incidence in renal transplant recipients - Endocrine Today PDF Print
Endocrine Today
In the study, 155 renal transplant recipients were randomly assigned to sirolimus (n=74) or immunosuppression therapy (n=81). Patients were evaluated every 3 months, and followed for 2 years, according to researchers. The adjusted relative risk for

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.